Using Extended Release Buprenorphine Injection to Discontinue Sublingual Buprenorphine: A Case Series

被引：5

作者：

Ritvo, Alexis D. ^{[1
]}

Calcaterra, Susan L. ^{[2
]}

Ritvo, Jonathan I. ^{[1
]}

机构：

[1] Univ Colorado, Sch Med, Dept Psychiat, Aurora, CO USA

[2] Univ Colorado, Sch Med, Div Gen Internal Med, Aurora, CO USA

来源：

JOURNAL OF ADDICTION MEDICINE | 2021年 / 15卷 / 03期

基金：

美国国家卫生研究院;

关键词：

discontinuation; extended release buprenorphine; sublingual buprenorphine; taper; withdrawal; OPIOID USE DISORDER; DOUBLE-BLIND; DURATION; OUTCOMES;

D O I：

10.1097/ADM.0000000000000738

中图分类号：

R194 [卫生标准、卫生检查、医药管理];

学科分类号：

摘要：

Buprenorphine is highly effective for the treatment of opioid use disorder and is increasingly being used in the treatment of chronic pain. For various reasons, patients on buprenorphine may request discontinuation of this medication. Tapering off buprenorphine can be challenging due to intolerable withdrawal symptoms, including nausea, malaise, anxiety, and dysphoria. A single dose of extended-release buprenorphine may facilitate discontinuation of buprenorphine by mitigating prolonged, debilitating opioid withdrawal symptoms. We report on three cases of successful transition from low dose sublingual buprenorphine to a single injection of 100 mg extended-release buprenorphine to opioid cessation in patients who had previously been unable to taper fully off buprenorphine. This novel use of extended-release buprenorphine provides a viable alternative to fully transition patients off buprenorphine when they are medically and emotionally ready.

引用

页码：252 / 254

页数：3

共 19 条

[1]

[Anonymous], 2015, BELBUCA BUPR BUCC FI

[2]

[Anonymous], 2019, CLIN REV REP BUPR EX

[3]

[Anonymous], 2014, BUTRANS BUPR TRANSD

[4]

[Anonymous], 2018, SUBUTEX BUPR SUB TAB

[5]

[Anonymous], 2019, SUBOXONE BUPR NAL SU

[6]

Blum Kenneth, 2013, J Addict Res Ther, V4, DOI 10.4172/2155-6105.1000146

[7] Sublingual Buprenorphine as an Analgesic in Chronic Pain: A Systematic Review [J].

Cote, Joyce ;

Montgomery, Lori .

PAIN MEDICINE, 2014, 15 (07) :1171-1178

[8] The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: A review [J].

Dunn, Kelly E. ;

Sigmon, Stacey C. ;

Strain, Eric C. ;

Heil, Sarah H. ;

Higgins, Stephen T. .

DRUG AND ALCOHOL DEPENDENCE, 2011, 119 (1-2) :1-9

[9] Effects of buprenorphine maintenance dose on μ-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers [J].

Greenwald, MK ;

Johanson, CE ;

Moody, DE ;

Woods, JH ;

Kilbourn, MR ;

Koeppe, RA ;

Schuster, CR ;

Zubieta, JK .

NEUROPSYCHOPHARMACOLOGY, 2003, 28 (11) :2000-2009

[10] Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [J].

Haight, Barbara R. ;

Learned, Susan M. ;

Laffont, Celine M. ;

Fudala, Paul J. ;

Zhao, Yue ;

Garofalo, Amanda S. ;

Greenwald, Mark K. ;

Nadipelli, Vijay R. ;

Ling, Walter ;

Heidbreder, Christian ;

Andersen, James L. ;

Bailey, Genie L. ;

Bartley, Scott Robert ;

Biunno, Michael J. ;

Boyett, Brent ;

Carr, Jesse M. ;

Cifuentes, Eduardo ;

Duarte-Sckell, Sandra Daniela ;

Dueno, Otto R. ;

Harrison, Boyde J. ;

Hassman, David R. ;

Hoffman, Kent Steven ;

Isacesu, Valentin ;

Ishaque, Saleem ;

Kakar, Rishi ;

Kampman, Kyle ;

Knapp, Richard D. ;

Konis, George ;

Kunovac, Jelena ;

Kwentus, Joseph A. ;

Levinson, Lawrence S. ;

Malhotra, Shishuka ;

Mehra, Vishaal ;

Mofsen, Ricky Stuart ;

Peyton, Marvin Lane ;

Pujari, Gita G. ;

Ranjan, Rakesh ;

Rutrick, Daniel ;

Seal, Gregory ;

Segal, Scott Daniel ;

Shiwach, Rajinder ;

Thomas, Haydn Mikel ;

Ventre, Peter Paul ;

Vijapura, Amit K. ;

Walling, David P. ;

Wiest, Katharina L. .

LANCET, 2019, 393 (10173) :778-790

← 1 2 →